STOCK TITAN

Regulus Therapeutics Inc - RGLS STOCK NEWS

Welcome to our dedicated news page for Regulus Therapeutics (Ticker: RGLS), a resource for investors and traders seeking the latest updates and insights on Regulus Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Regulus Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Regulus Therapeutics's position in the market.

Rhea-AI Summary
Regulus Therapeutics Inc. (Nasdaq: RGLS) will host investor meetings at the Wells Fargo Healthcare Conference and present at the H.C. Wainwright 25th Annual Global Investor Conference. Jay Hagan, President and CEO of Regulus, will give a live presentation on September 11, 2023, at 11:00 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.6%
Tags
none
-
Rhea-AI Summary
Regulus Therapeutics to host virtual investor event on September 6, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.19%
Tags
conferences
-
Rhea-AI Summary
Regulus Therapeutics reports financial results for Q2 2023 and provides corporate update. The Phase 1b MAD study of RGLS8429 for ADPKD is progressing, with dosing of the first patient in the second cohort. The company also strengthened its leadership team with new appointments. Cash position as of June 30, 2023, was $37.3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.5%
Tags
Rhea-AI Summary
Regulus Therapeutics Inc. (Nasdaq: RGLS) will have CEO Jay Hagan presenting at the Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023, at 11:30 a.m. ET. The live presentation will be available for replay on the company's website for 120 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.88%
Tags
conferences
-
Rhea-AI Summary
Regulus Therapeutics Inc. to present at the H.C. Wainwright 2nd Annual Kidney Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
management
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.15%
Tags
none
Rhea-AI Summary
Regulus Therapeutics Inc. announced the advancement to the second cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment of ADPKD. The company is pleased with the progress and expects topline data from the first cohort by the end of Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.45%
Tags
Regulus Therapeutics Inc

Nasdaq:RGLS

RGLS Rankings

RGLS Stock Data

183.30M
41.55M
1.41%
43.63%
8.28%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
San Diego

About RGLS

regulus therapeutics inc. (nasdaq:rgls) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting micrornas. regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microrna therapeutics pipeline complemented by a maturing micromarkerssm biomarkers platform and a rich intellectual property estate to retain its leadership in the microrna field. regulus is developing rg-101, a galnac-conjugated anti-mir targeting microrna-122 for the treatment of chronic hepatitis c virus infection, and rg-012, an anti-mir targeting microrna-21 for the treatment of alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy. in addition, rg-125, a galnac-conjugated anti-mir targeting microrna-103/107 for the treatment of nash in patients with type 2 diabetes/pre-diabetes, has entered phase i clinical development through its strategic alliance with astrazeneca. reg